Loic Guillevin

Summary

Country: France

Publications

  1. ncbi Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach
    Alexis Régent
    Inserm U1016, Institut Cochin, CNRS UMR 8104, 8 rue Mechain, F 75014 Paris, France
    Arthritis Res Ther 13:R107. 2011
  2. ncbi [La Presse Médicale: a step forward]
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Paris
    Presse Med 35:1-2. 2006
  3. ncbi Virus-induced systemic vasculitides: new therapeutic approaches
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, AP HP, Universite Rene Descartes Paris V, 27, rue du Faubourg Saint Jacques, Paris, France
    Clin Dev Immunol 11:227-31. 2004
  4. ncbi [Necrosing vasculitis]
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Paris
    Rev Prat 54:1513-4. 2004
  5. ncbi Clinical pictures of and therapeutic strategies for systemic vasculitides
    L Guillevin
    , , , , 27, rue du Faubourg Saint-Jacques, 75679 Paris 14, France
    Autoimmun Rev 3:S49-51. 2004
  6. ncbi Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa
    L Guillevin
    Centre Hospitalier Universitaire Avicenne, Bobigny, France
    Arthritis Rheum 51:482-7. 2004
  7. ncbi [Twenty-seven years' activities of the French vasculitis study group (FVSG)]
    L Guillevin
    , , , , AP-HOP, , 27 rue du Faubourg-Saint-Jacques, 75014 Paris, France
    Rev Med Interne 28:S263-5. 2007
  8. ncbi [Pericarditis in internal medicine]
    L Guillevin
    , , , 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
    Rev Med Interne 28:S20-1. 2007
  9. ncbi Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Medicine (Baltimore) 84:313-22. 2005
  10. ncbi Therapeutic strategies for systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, Paris, France
    Allergol Int 56:105-11. 2007

Collaborators

Detail Information

Publications74

  1. ncbi Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach
    Alexis Régent
    Inserm U1016, Institut Cochin, CNRS UMR 8104, 8 rue Mechain, F 75014 Paris, France
    Arthritis Res Ther 13:R107. 2011
    ..We thus decided to detect autoantibodies directed against endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) in the serum of GCA patients and to identify their target antigens...
  2. ncbi [La Presse Médicale: a step forward]
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Paris
    Presse Med 35:1-2. 2006
  3. ncbi Virus-induced systemic vasculitides: new therapeutic approaches
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, AP HP, Universite Rene Descartes Paris V, 27, rue du Faubourg Saint Jacques, Paris, France
    Clin Dev Immunol 11:227-31. 2004
    ..In vasculitis related to HCV-associated cryoglobulinemia, plasma exchanges improve the outcome but the poor effectiveness of antiviral drugs is not able to favor, usually, a definite recovery of the patients and relapses are frequent...
  4. ncbi [Necrosing vasculitis]
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Paris
    Rev Prat 54:1513-4. 2004
  5. ncbi Clinical pictures of and therapeutic strategies for systemic vasculitides
    L Guillevin
    , , , , 27, rue du Faubourg Saint-Jacques, 75679 Paris 14, France
    Autoimmun Rev 3:S49-51. 2004
  6. ncbi Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa
    L Guillevin
    Centre Hospitalier Universitaire Avicenne, Bobigny, France
    Arthritis Rheum 51:482-7. 2004
    ..To assess the efficacy and safety of lamivudine, an antiviral agent that strongly inhibits hepatitis B virus (HBV) DNA replication, combined with plasma exchanges after short-term corticosteroids for HBV-related polyartertitis nodosa (PAN)...
  7. ncbi [Twenty-seven years' activities of the French vasculitis study group (FVSG)]
    L Guillevin
    , , , , AP-HOP, , 27 rue du Faubourg-Saint-Jacques, 75014 Paris, France
    Rev Med Interne 28:S263-5. 2007
  8. ncbi [Pericarditis in internal medicine]
    L Guillevin
    , , , 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
    Rev Med Interne 28:S20-1. 2007
  9. ncbi Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Medicine (Baltimore) 84:313-22. 2005
    ..The major cause of death is gastrointestinal tract involvement. Importantly, the frequency of HBV-PAN has decreased in relation to improved blood safety and vaccination campaigns...
  10. ncbi Therapeutic strategies for systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, Paris, France
    Allergol Int 56:105-11. 2007
    ..Some of them have achieved promising positive effects, for example, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials...
  11. ncbi [Treatment of ANCA-associated vascularitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:922-7. 2007
    ..These biologics must be prescribed extremely cautiously and only in trial settings, especially in view of the adverse effects, few but severe, recently been reported with them...
  12. ncbi Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients
    Camillo Ribi
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Arthritis Rheum 58:586-94. 2008
    ....
  13. ncbi Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 62:616-26. 2010
    ..This study was undertaken to describe the main characteristics of and long-term outcomes in patients with well-characterized PAN diagnoses...
  14. ncbi Azathioprine or methotrexate maintenance for ANCA-associated vasculitis
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    N Engl J Med 359:2790-803. 2008
    ..However, azathioprine and methotrexate have not been compared with regard to safety and efficacy...
  15. ncbi Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients
    Pascal Cohen
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Université René Descartes Paris, Recherche Clinique et Thérapeutique, Paris, France
    Arthritis Rheum 57:686-93. 2007
    ..To compare long and short durations of adjunctive cyclophosphamide for the treatment of severe Churg-Strauss syndrome (CSS)...
  16. ncbi IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients
    Paloma Garcia de la Pena-Lefebvre
    UPRES EA 3408, UFR SMBH Leonard de Vinci, Bobigny, France
    Clin Immunol 111:241-51. 2004
    ..Our results indicate that Ab from patients with limited or diffuse SSc with or without anti-topo 1 Ab exhibit specific and mutually exclusive reactivity patterns...
  17. ncbi The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
    Eric Hachulla
    Hopital Claude Huriez, Department of Internal Medicine, National Reference Center for Scleroderma, and University of Lille, Lille, France
    Arthritis Rheum 60:1831-9. 2009
    ..85%. The aim of this observational study was to investigate the incidence of PAH and pulmonary hypertension (PH) during a 3-year followup of patients from the same cohort (the ItinérAIR-Sclérodermie Study)...
  18. ncbi Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients
    Camillo Ribi
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 75679 Paris, France
    Arthritis Rheum 62:1186-97. 2010
    ....
  19. ncbi Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)
    Amélie Servettaz
    Universite Paris Descartes, Faculte de Medecine, UPRES EA 1833, Laboratoire d Immunologie, Paris, France
    Clin Immunol 120:212-9. 2006
    ..The main target of anti-endothelial cell antibodies in patients with limited cutaneous SSc is the nuclear and ubiquitous protein CENP-B...
  20. ncbi Patient preference disability questionnaire in systemic sclerosis: a cross-sectional survey
    Luc Mouthon
    Paris Descartes University, UPRES EA 4058, and Assistance Publique Hopitaux de Paris, Cochin Hospital, Paris, France
    Arthritis Rheum 59:968-73. 2008
    ..To assess patient priorities concerning disability in systemic sclerosis (SSc)...
  21. ncbi Employment status and socio-economic burden in systemic sclerosis: a cross-sectional survey
    Christelle Nguyen
    Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Paris, France
    Rheumatology (Oxford) 49:982-9. 2010
    ..To assess employment status and socio-economic burden in SSc patients...
  22. ncbi [Microscopic polyangiitis]
    Christian Pagnoux
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites nécrosantes et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:895-901. 2007
    ..Biological therapies are under evaluation. The remission rate is above 80% with these regimens, and the relapse rate is around 30% at 5 years, lower than for Wegener's granulomatosis...
  23. ncbi Cardiac magnetic resonance imaging in Churg-Strauss-syndrome. Impact of immunosuppressants on outcome assessed in a prospective study on 8 patients
    Julien Marmursztejn
    Department of Cardiology, Hopital Cochin, UNIVERSITE DE PARIS, France
    Clin Exp Rheumatol 28:8-13. 2010
    ..To evaluate the effects of immunosuppressive therapy on cardiac abnormalities observed by cardiac magnetic resonance imaging (CMRI) in patients with Churg-Strauss syndrome (CSS)...
  24. ncbi Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome
    Régis Sablé-Fourtassou
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris 5 Rene Descartes, Paris, France
    Ann Intern Med 143:632-8. 2005
    ..Since testing for antineutrophil cytoplasmic antibodies (ANCA) became available for routine evaluation, no large homogeneous cohort of patients with the Churg-Strauss syndrome has been studied...
  25. ncbi Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis
    Christelle Nguyen
    Universite Paris Descartes, Faculté de Médecine Paris Descartes, Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 6:e17551. 2011
    ..To assess the association of gender with clinical expression, health-related quality of life (HRQoL), disability, and self-reported symptoms of depression and anxiety in patients with systemic sclerosis (SSc)...
  26. ncbi [Interstitial lung disease in systemic sclerosis]
    Luc Mouthon
    Service de Medecine Interne, Hopital Cochin, Centre de Référence pour les Vascularites et la Sclérodermie Systémique, AP HP, Paris
    Presse Med 35:1943-51. 2006
    ..A subgroup of patients with rapidly progressive ILD might benefit from intravenous cyclophosphamide pulses in association with 15 mg/d prednisone...
  27. ncbi Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris, Paris, France
    Isr Med Assoc J 10:89-91. 2008
    ..Some of them (e.g., anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies) have achieved promising results and are now often used to treat severe cases...
  28. ncbi Sensitivity to change in systemic sclerosis of the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR): shift in patient priorities over time
    Christelle Nguyen
    Paris Descartes University, UPRES EA 4058, Department of Internal Medicine, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Cochin Hospital, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    J Rheumatol 37:359-64. 2010
    ..To assess the sensitivity to change of the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR) in systemic sclerosis (SSc) and a shift in patient priorities over time...
  29. ncbi Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy
    Benjamin Terrier
    Assistance Publique Hopitaux de Paris, Hopital de Bicetre, Le Kremlin Bicetre, France
    Arthritis Rheum 57:1520-9. 2007
    ..To evaluate the clinicobiologic presentation in patients with primary Sjögren's syndrome (SS)-related peripheral neuropathy, the histologic results of neuromuscular biopsy (NMB), and clinical outcome, and to identify prognostic factors...
  30. ncbi Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
    Eric Hachulla
    Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, 59037 Lille Cedex, France
    Rheumatology (Oxford) 48:304-8. 2009
    ..This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline...
  31. ncbi Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach
    Amélie Servettaz
    Faculte de Medecine, UPRES EA 4058, Universite Paris Descartes, Paris, France
    Proteomics 8:1000-8. 2008
    ..IgG from all of the healthy individuals tested recognized a restricted set of highly conserved ubiquitous proteins playing key roles in cell biology and maintenance of homeostasis...
  32. ncbi [Therapeutic management of systemic sclerosis]
    Luc Mouthon
    Service de Medecine Interne, Hopital Cochin, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Faculte de Medecine
    Presse Med 35:1975-82. 2006
    ..Physical therapy and rehabilitation may help to treat disability and loss of function in SSc patients...
  33. ncbi Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Paris Cedex 14, France
    Rheumatology (Oxford) 51:460-7. 2012
    ..This study was undertaken to describe SRC characteristics, prognosis and outcome, and evaluate the responsibility of CSs in its occurrence...
  34. ncbi Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients
    Alex Kostianovsky
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Sorbonne Paris Cité, INSERM U1060, Referral Center for Rare Autoimmune Systemic Diseases, Paris, France
    Clin Exp Rheumatol 30:S83-9. 2012
    ..This study was undertaken to evaluate immunogenicity and tolerance of seasonal (SFV) and A/H1N1 flu vaccines (HFV) in AID patients...
  35. ncbi Is pulmonary arterial hypertension really a late complication of systemic sclerosis?
    Eric Hachulla
    Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, 59037 Lille Cedex, France
    Chest 136:1211-9. 2009
    ..PAH is generally considered to be a late complication of limited cutaneous SSc. This study identified and investigated a subset of SSc patients with early-onset PAH...
  36. ncbi Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration
    Alfred Mahr
    Department of Internal Medicine, Universite Paris 5 Rene Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 58:3951-9. 2008
    ..To estimate the prevalence of Behçet's disease (BD) in a multiethnic population living in France, with particular focus on disease risk among immigrants...
  37. ncbi Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts
    Christian Pagnoux
    Hopital Cochin, AP HP, UNIVERSITE DE PARIS, Paris, France
    Arthritis Rheum 58:2908-18. 2008
    ..This study was undertaken to evaluate the applicability of those predictors in an independent cohort followed up by the French Vasculitis Study Group...
  38. ncbi Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome
    Eric Hachulla
    Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, France
    Rheumatology (Oxford) 49:940-4. 2010
    ..To describe the history of SSc-associated pulmonary arterial hypertension (SSc-PAH) in patients with New York Heart Association (NYHA) functional class (FC) II dyspnoea at diagnosis...
  39. ncbi Differences in patients with systemic sclerosis recruited from associations and tertiary care settings
    Caroline Mestre-Stanislas
    Universite Paris Descartes, Faculte de Medecine, Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Presse Med 39:e205-9. 2010
    ..To compare patients with systemic sclerosis (SSc) recruited from a patient association or a tertiary care setting...
  40. ncbi [Classification of systemic vasculitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence maladies rares Vascularites et Sclérodermies systémiques, Hopital Cochin, université Paris V René Descartes, Paris
    Rev Prat 58:480-6. 2008
    ....
  41. ncbi Extraocular manifestations of birdshot chorioretinopathy in 118 French patients
    Christian Pagnoux
    Department of Internal Medicine, National referral center for Systemic necrotizing vasculitides and systemic scleroderma, Hopital Cochin, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, 75879 Paris cedex 14, France
    Presse Med 39:e97-e102. 2010
    ..Published studies on birdshot chorioretinopathy (BCR) did not provide definitive information on possibly associated extraocular manifestations...
  42. ncbi Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension
    Benjamin Terrier
    Laboratoire d Immunologie, UPRES EA 4058, Pavillon Gustave Roussy, 4e Etage, Paris Descartes University, 8 rue Mechain, 75014 Paris, France
    Am J Respir Crit Care Med 177:1128-34. 2008
    ....
  43. ncbi Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement
    Jacques Eric Gottenberg
    Department of Internal Medicine, Nationale referral center for Vasculitides and Scleroderma, Hopital Cochin, AP HP, Universite Paris 5, Paris
    Presse Med 36:771-8. 2007
    ..This prospective study sought to assess the long-term outcome and identify prognostic factors of patients with kidney disease related to Wegener's granulomatosis (WG)...
  44. ncbi Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma
    Hanadi Dib
    Inserm U1016, Institut Cochin, Paris, France
    Eur Respir J 39:1405-14. 2012
    ....
  45. ncbi Delayed relapse of Churg-Strauss syndrome manifesting as colon ulcers with mucosal granulomas: 3 cases
    Nathalie Memain
    Rheumatology Department, Bichat Teaching Hospital, Paris, France
    J Rheumatol 29:388-91. 2002
    ..We describe 3 new cases of colonic ulcers in CSS. Unusual features were diagnosis of the ulcers during a delayed relapse and presence of eosinophilic granulomas within the mucosa...
  46. ncbi Lymphoma complicating common variable immunodeficiency with granulomatous disease: report of two cases
    Véronique Le Guern
    Department of Internal Medicine, Hopital Avicenne, Assistance Publique Hôpitaux de Paris and Université Paris Nord, Bobigny, France
    Eur J Haematol 71:459-63. 2003
    ..We describe two CVID patients with systemic granulomatosis who developed B-cell lymphomas, one related to Epstein Barr virus infection, 5 and 12 yr after CVID had been diagnosed...
  47. ncbi Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients
    Valerie Martinez
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Arthritis Rheum 58:308-17. 2008
    ....
  48. ncbi Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment
    Bertrand Dunogué
    Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases including Vasculitis, Scleroderma, Hopital Cochin, Assistance Publique Hopitaux de Paris, France
    Semin Respir Crit Care Med 32:298-309. 2011
    ..Future therapies might reflect these differences more strongly...
  49. ncbi Therapeutic options for systemic sclerosis related interstitial lung diseases
    Luc Mouthon
    Universite Paris Descartes, UPRES EA 4058, Pôle de Médecine Interne et Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Respir Med 104:S59-69. 2010
    ..A subgroup of patients with rapidly progressive ILD might benefit from pulsed intravenous cyclophosphamide combined with prednisone 15 mg daily but this remains to be confirmed...
  50. ncbi Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations
    Guillaume Bussone
    Universite Paris Descartes, Faculte de Medecine, UPRES EA 4058, Paris, France
    Proteomics 9:2253-62. 2009
    ..Overall, 96 proteins were identified by MS. Fourteen were recognized in both extracts including glycolysis proteins such as alpha-enolase, RNA processing and cytoskeletal proteins such as lamin-A/C...
  51. ncbi Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse
    Amélie Servettaz
    Universite Paris Descartes, Faculte de Medecine, EA1833, Paris, France
    J Immunol 182:5855-64. 2009
    ..Moreover, this demonstration is the first that shows the specific oxidation of an autoantigen directly participates in the pathogenesis of an autoimmune disease...
  52. ncbi [Classification of systemic vasculatides]
    Loic Guillevin
    Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:845-53. 2007
    ....
  53. ncbi Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo
    Jerome Alexandre
    UPRES 1833, Groupe Hospitalier Cochin, Assistance Publique Hopitaux de Paris, faculté de médecine Paris 5, France
    Int J Cancer 119:41-8. 2006
    ..These results suggest that ROS participate in vitro and in vivo to paclitaxel cytotoxicity...
  54. ncbi Microscopic polyangiitis and polyarteritis nodosa: how and when do they start?
    Christian Agard
    Hopital Avicenne, Assistance Publique Hopitaux de Paris, France
    Arthritis Rheum 49:709-15. 2003
    ..To describe initial clinical symptoms attributable to microscopic polyangiitis (MPA) or polyarteritis nodosa (PAN)...
  55. ncbi Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database
    Christian Pagnoux
    Department of Internal Medicine, Hopital Cochin, 75879 Paris cedex 14, France
    J Rheumatol 38:475-8. 2011
    ..To study the frequency and characteristics of patients with Wegener's granulomatosis (WG) strictly and persistently localized to one organ...
  56. ncbi Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial
    Raphaele Seror
    Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Ann Rheum Dis 69:2125-30. 2010
    ....
  57. ncbi Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses
    Cecile Marchand-Janssen
    Universite Paris Descartes, Faculte de Medecine, INSERM, CIC BT505, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Cochin Saint Vincent De Paul, Pôle de médecine, CIC de vaccinologie Cochin Pasteur, Paris, France
    Rheumatology (Oxford) 50:1099-105. 2011
    ..To evaluate vaccine coverage and humoral immunity to tetanus, diphtheria and poliomyelitis in adults followed for systemic inflammatory and/or autoimmune diseases (SIADs)...
  58. ncbi Indications for biotherapy in systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, French Vasculitis Study Group, Centre de Référence Vascularites et Sclérodermie, Hopital Cochin, Universite Paris Descartes, Paris, France
    Clin Rev Allergy Immunol 32:85-96. 2007
    ..Results of international ongoing trials will determine whether the agents may also have a place as first-line treatment...
  59. ncbi Indication for plasma exchange for systemic necrotizing vasculidities
    Loic Guillevin
    Department of Internal Medicine, Referral Center for Rare Diseases, Vasculitis and Scleroderma, Hopital Cochin, AP HP, Université de Paris René Descartes, 27, rue du Faubourg Saint Jacques, Paris, France
    Transfus Apher Sci 36:179-85. 2007
    ..Although PE does not improve survival, their adjunction to corticosteroids and immunosuppressants for patients with alveolar hemorrhage could also limit the severity of this severe manifestation...
  60. ncbi Serum eosinophil cationic protein: a marker of disease activity in Churg-Strauss syndrome
    Philippe Guilpain
    Paris Descartes University, Faculty of Medicine, Cochin Hospital, Paris, France
    Ann N Y Acad Sci 1107:392-9. 2007
    ..6264; P < 0.05) and during periods of remission (R = 0.4798; P < 0.05). Our results support that ECP might be used as a disease activity marker in CSS...
  61. ncbi Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients
    Mathilde de Menthon
    Department of Internal Medicine, Hopital Cochin, University Paris Descartes, Paris, France
    Clin Exp Rheumatol 29:S63-71. 2011
    ..To compare efficacy and tolerance of infliximab versus rituximab to treat refractory Wegener's granulomatosis (WG), and clarify their respective indications...
  62. ncbi Advances in the treatments of systemic vasculitides
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, 27 rue du Faubourg Saint Jacques, Paris, France
    Clin Rev Allergy Immunol 35:72-8. 2008
    ..The strategies that improve patient's outcome are discussed in the light of the prospective trials organized by international research groups...
  63. ncbi The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort
    Loic Guillevin
    Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases Vasculitides and Scleroderma, Hopital Cochin, Assistance Publique Hopitaux de Paris, UPRES 4058, Universite Paris Descartes, INSERM 1016, Paris, France loic guillevin cch aphp fr
    Medicine (Baltimore) 90:19-27. 2011
    ..The better WG prognosis for patients with ENT manifestations, even for patients with other visceral involvement, compared with the prognosis for those without ENT manifestations, probably reflects WG phenotype heterogeneity...
  64. ncbi Thiabendazole-induced acute liver failure requiring transplantation and subsequent diagnosis of polyarteritis nodosa
    Matthieu Groh
    Department of Internal Medicine, Hopital Cochin, Referral Center for Rare Autoimmune and Systemic Diseases, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Clin Exp Rheumatol 30:S107-9. 2012
    ..His outcome was favourable after second OLT, under steroids, cyclophosphamide pulses and tacrolimus. In retrospect, his initial symptoms and hypereosinophilia were probably attributable to PAN...
  65. ncbi Anti-PL7 antisynthetase syndrome under interferon therapy
    Achille Aouba
    Department of Adult Haematology, Necker Enfants Malades Hospital, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 149, rue de Sevres, 75015 Paris, France
    Joint Bone Spine 78:94-7. 2011
    ....
  66. ncbi Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies
    Philippe Guilpain
    Paris Descartes University, Faculty of Medicine, UPRES EA 4058, Department of Internal Medicine, Paris, France
    Autoimmun Rev 7:421-5. 2008
    ..Thus, anti-MPO Abs could play a pathogenic role in vivo by triggering an oxidative burst leading to severe endothelial damages...
  67. ncbi IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts
    Mathieu C Tamby
    Paris Descartes University, Faculty of Medicine, UPRES EA 4058, Paris, France
    Biologics 2:583-91. 2008
    ..These two bands were further identified as DNA topoisomerase 1. Our results indicate that IgG from patients with diffuse systemic sclerosis bind DNA topoisomerase 1 in normal human fibroblasts extracts...
  68. ncbi Low influenza vaccination rate among patients with systemic sclerosis
    Luc Mouthon
    Department of Internal Medicine, Cochin Hospital, Paris Cedex 14, France
    Rheumatology (Oxford) 49:600-6. 2010
    ..To evaluate the influenza vaccination rate and factors influencing it in patients with SSc...
  69. ncbi Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects
    Achille Aouba
    Department of Internal Medicine and the French Vasculitis Study Group, Assistance Publique Hopitaux de Paris, Universite Paris, 5 René Descartes, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679, Paris Cedex 14, France
    Clin Rev Allergy Immunol 34:65-73. 2008
    ..This promising biotherapy opens the way for other therapeutic agents targeting B lymphocytes and to improve our understanding of the pathophysiology of ANCA-associated vasculitis...
  70. ncbi Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Alice Berezne
    Paris Descartes University, Faculty of Medicine, UPRES EA 4058, Department of Internal Medicine and Reference Center for Necrotizing Vasculitides and Systemic Sclerosis, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ann N Y Acad Sci 1110:271-84. 2007
    ..Since only a minority of SSc patients develops severe ILD, we propose that further studies evaluating CYC should focus on the subgroup of SSc patients with worsening ILD...
  71. ncbi Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies
    Christian Pagnoux
    Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 27, rue du Faubourg Saint Jacques, 75879 Paris cedex 14, France
    Joint Bone Spine 77:604-7. 2010
    ....
  72. ncbi [Treatment of systemic autoimmune and inflammatory diseases with rituximab]
    Guillaume Bussone
    Universite Paris Descartes, Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, F 75679 Paris cedex 14, France
    Presse Med 38:808-23. 2009
    ..Relapses of the disease are common around six months after rituximab infusion. The response to retreatment with rituximab is usually the same that was obtained after the first course of treatment...
  73. ncbi [Flu vaccine and auto-immune and/or inflammatory diseases]
    Paula Duchet-Niedziolka
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris AP HP, Hopital Cochin, Centre d Investigation Clinique de Vaccinologie Cochin Pasteur, INSERM, CIC BT505, Paris, France
    Presse Med 40:248-52. 2011
    ..More data are needed about the severity of influenza infection and the efficacy of influenza vaccination in patients with systemic inflammatory and/or autoimmune diseases to improve their vaccine coverage...
  74. ncbi Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated
    Christian Pagnoux
    Hopital Cochin, Service de Medecine Interne, 27, rue du Faubourg Saint Jacques, Paris Cedex 14, France
    Medicine (Baltimore) 84:115-28. 2005
    ....